First Peer-Reviewed Publication Validating Cardica's C-Port(R) Systems Efficacy in Beating-Heart Bypass Procedures Using Arterial Grafts

Cardica, Inc. (Nasdaq: CRDC) today announced the publication of a study demonstrating that the use of its anastomosis (stapling) devices provides a safe and effective means to connect arterial grafts during beating-heart coronary artery bypass graft (CABG) procedures. The study, which was published in the March/April issue of the official journal of the International Society of Minimally-Invasive Cardiothoracic Surgery, Innovations, evaluated the safety and efficacy of Cardica's C-Port xA® Distal and Flex-A® Anastomosis Systems (C-Port xA and Flex-A) during beating-heart coronary artery bypass graft (CABG) procedures. Results showed that Cardica's anastomosis systems connected arterial grafts consistently and effectively during bypass procedures performed on a beating heart without the use of a heart-lung machine, and that these grafts remained open in short and mid-term follow-up.

STAAR Surgical Expects 12% First Quarter Revenue Growth From Continuing Operations

STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that revenue for the first quarter ended April 3, 2010 grew approximately 12% as compared to the first quarter of 2009. In addition, the Company announced several developments at the American Society of Cataract and Refractive Surgeons (ASCRS) annual conference which continues through Tuesday, April 13, in Boston.

On March 2, 2010, STAAR divested its German distribution subsidiary, Domilens GmbH. Operating results for the first quarter of 2010 will not include any contribution from Domilens, which has been classified as discontinued operations. Comparative historic results have also been restated to reflect the discontinued status of the Domilens operations. The Company currently expects to report its final first quarter results in early May, and those results will include a gain from the divesture of Domilens.

ALDA Receives FDA Permission to Sell Products in the US

ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCBB: APCSF) ("ALDA") is pleased to announce that a "NDC" (National Drug Code) Labeller Code has been assigned to the Company by the US Food and Drug Administration ("FDA"). The NDC number allows the Company to sell OTC monograph products in the US.

Dr. Terrance Owen, President & CEO, states, "Receiving the NDC number from the FDA provides ALDA with the consent that is needed to introduce our products in the US. This is the first step in fulfilling our strategy of securing foreign sales for current products while we continue to pursue the testing and registration of the T36(R) therapeutics".

PURE Bioscience Receives U.S. EPA Registration for SDC-Based Disinfectant and Food Contact Surface Sanitizer

PURE Bioscience (NASDAQ: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, announced today that it has received U.S. Environmental Protection Agency (EPA) registration for its SDC-based disinfectant and food contact surface sanitizer. The product will be marketed as IV-7 Ultimate Germ Defense for Food Contact Surfaces™ (IV-7) by PURE’s sales and marketing representative, Richmont Sciences, LLC. An EPA Category IV disinfectant/sanitizer, IV-7 provides an advantageous combination of high efficacy, low toxicity and efficiency by rapidly eliminating dangerous pathogens, yet no rinse is required.